BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27403255)

  • 1. Effect of WR-1065 on 6-hydroxydopamine-induced catalepsy and IL-6 level in rats.
    Kheradmand A; Nayebi AM; Jorjani M; Haddadi R
    Iran J Basic Med Sci; 2016 May; 19(5):490-6. PubMed ID: 27403255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats.
    Haddadi R; Mohajjel Nayebi A; Brooshghalan SE
    Neurosci Lett; 2013 Oct; 555():106-11. PubMed ID: 24045063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc.
    Haddadi R; Poursina M; Zeraati F; Nadi F
    Inflammopharmacology; 2018 Oct; 26(5):1305-1316. PubMed ID: 29616453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Term Treatment with Silymarin Improved 6-OHDA-Induced Catalepsy and Motor Imbalance in Hemi-Parkisonian Rats.
    Haddadi R; Eyvari Brooshghalan S; Farajniya S; Mohajjel Nayebi A; Sharifi H
    Adv Pharm Bull; 2015 Nov; 5(4):463-9. PubMed ID: 26819917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats.
    Haddadi R; Nayebi AM; Eyvari Brooshghalan S
    Biomed Pharmacother; 2018 Aug; 104():127-136. PubMed ID: 29772432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines.
    Kheradmand A; Nayebi AM; Jorjani M; Khalifeh S; Haddadi R
    Neurosci Lett; 2016 Aug; 627():7-12. PubMed ID: 27222379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats.
    Sharifi H; Mohajjel Nayebia A; Farajnia S
    Adv Pharm Bull; 2012; 2(1):127-31. PubMed ID: 24312782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
    Sharifi H; Nayebi AM; Farajnia S; Haddadi R
    Drug Res (Stuttg); 2015 Aug; 65(8):393-7. PubMed ID: 24782287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats.
    Sharifi H; Mohajjel Nayebi A; Farajnia S
    Iran J Basic Med Sci; 2013 Dec; 16(12):1270-5. PubMed ID: 24570834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors.
    Sharifi H; Mohajjel Nayebia A; Farajnia S
    Adv Pharm Bull; 2013; 3(1):203-6. PubMed ID: 24312836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
    Mahmoudi J; Nayebi AM; Samini M; Reyhani-Rad S; Babapour V
    Pharmacol Rep; 2011; 63(4):908-14. PubMed ID: 22001978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of 5-Hydroxytryptamine 1A Receptors in 6-Hydroxydopmaine-induced Catalepsy-like Immobilization in Rats: a Therapeutic Approach for Treating Catalepsy of Parkinson's Disease.
    Eyhani-Rad S; Mohajjel Nayebi A; Mahmoudi J; Samini M; Babapour V
    Iran J Pharm Res; 2012; 11(4):1175-81. PubMed ID: 24250551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling.
    Eyvari Brooshghalan S; Sabahi M; Ebadi SA; Sadeghian Z; Mohajjel Nayebi A; Haddadi R
    Eur J Pharmacol; 2023 Feb; 941():175517. PubMed ID: 36669615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post treatment with Gastrodin suppresses oxidative stress and attenuates motor disorders following 6-OHDA induced Parkinson disease.
    Sadeghian Z; Eyvari-Brooshghalan S; Sabahi M; Nourouzi N; Haddadi R
    Neurosci Lett; 2022 Nov; 790():136884. PubMed ID: 36162540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
    Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
    Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats.
    Nayebi AM; Rad SR; Saberian M; Azimzadeh S; Samini M
    Pharmacol Rep; 2010; 62(2):258-64. PubMed ID: 20508280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
    Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F
    Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.
    Yang J; Hu LF; Liu X; Zhou F; Ding JH; Hu G
    Life Sci; 2006 Mar; 78(17):1940-4. PubMed ID: 16216278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.
    Zhang FL; He Y; Zheng Y; Zhang WJ; Wang Q; Jia YJ; Song HL; An HT; Zhang HB; Qian YJ; Tong YL; Dong L; Wang XM
    CNS Neurosci Ther; 2014 Dec; 20(12):1036-44. PubMed ID: 25399812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: neuroprotection by serotonin, GABA and bone marrow cells supplementation.
    Kuruvilla KP; Nandhu MS; Paul J; Paulose CS
    J Neurol Sci; 2013 Aug; 331(1-2):31-7. PubMed ID: 23726276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.